Abstract: In the invention described here, the approach is to formulate an edible vaccine based on N-terminal yeast surface display expression platform that producing S.cerevisiae EBY100/pYD5-preS2/S(adw) and S.cerevisiae EBY100/pYD5-preS2/S(adr) for protecting and treating human against hepatitis B virus (HBV) infection, suggesting that yeast surface display expression system expressing HBsAg antigen has potential as a prophylactic treatment for HBV in human via oral vaccination. The technology developed in this patent application can also be used to produce edible (oral) vaccines for preventing and treating other infectious diseases in human.